Editas Medicine (EDIT) Cash from Investing Activities (2015 - 2025)

Editas Medicine (EDIT) has 11 years of Cash from Investing Activities data on file, last reported at $39.6 million in Q3 2025.

• On a quarterly basis, Cash from Investing Activities fell 52.88% year-over-year to $39.6 million in Q3 2025; TTM through Sep 2025 was $169.6 million, a 12.61% decrease from a year earlier, with the FY2024 full-year figure at $162.1 million, up 4445.91% from the prior year.
• Cash from Investing Activities for Q3 2025 stood at $39.6 million, down from $42.6 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for EDIT reached as high as $89.2 million in Q3 2022 and fell as low as -$102.8 million in Q3 2023.
• Historically, Cash from Investing Activities has averaged $18.8 million across 5 years, with a median of $23.3 million in 2023.
• Across the five-year window, Cash from Investing Activities soared 1637.7% in 2022 and slumped 215.23% in 2023, its largest moves.
• Year by year, Cash from Investing Activities stood at -$22.8 million in 2021, then decreased by 20.53% to -$27.5 million in 2022, then jumped by 328.28% to $62.8 million in 2023, then tumbled by 50.74% to $31.0 million in 2024, then climbed by 27.83% to $39.6 million in 2025.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were $39.6 million in Q3 2025, $42.6 million in Q2 2025, and $56.4 million in Q1 2025.